[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363472-105":59,"doc-detail-363472-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","effects-of-dyslipidemia-on-fertility-sparing-treatment-outcomes-in-endometrial-atypical-hyperplasia-and-endometrial-cancer-a-large-cohort-study","Effects of dyslipidemia on fertility-sparing treatment outcomes in endometrial atypical hyperplasia and endometrial cancer - a large cohort study","","Investigate whether dyslipidemia affects fertility-preserving treatment outcomes in patients with endometrioid endometrial cancer or endometrial atypical hyperplasia. A total of 406 patients treated from January 2017 to December 2020 were grouped by dyslipidemia status and compared for 16- and 32-week complete response, pregnancy outcomes, and recurrence. Mixed dyslipidemia showed a lower 32-week complete response rate and longer time to achieve complete response. Mixed dyslipidemia remained an independent risk factor, especially in those with both overweight and mixed dyslipidemia, indicating worse conservative outcomes.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/effects-of-dyslipidemia-on-fertility-sparing-treatment-outcomes-in-endometrial-atypical-hyperplasia-and-endometrial-cancer-a-large-cohort-study/363472/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/effects-of-dyslipidemia-on-fertility-sparing-treatment-outcomes-in-endometrial-atypical-hyperplasia-and-endometrial-cancer-a-large-cohort-study/363472.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main purpose?","Question",{"text":112,"@type":113},"To assess how dyslipidemia influences outcomes of fertility-preserving treatment in patients with endometrioid endometrial cancer or endometrial atypical hyperplasia.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients received fertility-sparing treatment, and what groups were compared?",{"text":117,"@type":113},"406 patients were included and divided into dyslipidemia (n=282) and non-dyslipidemia (n=124) groups based on lipid status.",{"name":119,"@type":110,"acceptedAnswer":120},"Did dyslipidemia affect complete response, pregnancy outcomes, and recurrence?",{"text":121,"@type":113},"Overall, 16- and 32-week complete response rates, pregnancy-related outcomes, and recurrence did not differ significantly between patients with and without dyslipidemia.",{"name":123,"@type":110,"acceptedAnswer":124},"What was the key finding regarding mixed dyslipidemia?",{"text":125,"@type":113},"Mixed dyslipidemia was associated with a lower 32-week complete response rate and longer treatment duration to achieve complete response, and it was identified as an independent risk factor, particularly in overweight patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},363472,1790197886,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEffects of dyslipidemia on fertilitysparing treatment outcomes in endometrial atypical hyperplasia and endometrial cancer: a large cohort study  \nShuhan Luo1,3, ManrongWang1,3, Weiwei Shan1, Lulu Wang1, Sijia Liu1, Qujia Gama1, Xuezhen Luo1,2􀀍 & Pengfei Wu1,2􀀍  \nThis study aimed to investigate the impact of dyslipidemia on outcomes of fertility-preserving treatment in patients with endometrioid endometrial cancer (EEC) or endometrial atypical hyperplasia (EAH). A total of 406 patients, including 118 EEC and 288 EAH, who received fertility-sparing treatment between January 2017 and December 2020 were included and divided into a dyslipidemia group (n = 282) and a non-dyslipidemia group (n = 124). The 16-/32-week complete response (CR) rate, pregnancy outcome, and recurrence were compared between patients with and without dyslipidemia. Furthermore, we explored the effect of different indicators of dyslipidemia, including total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), on the therapeutic effects of fertility-preserving treatment. A total of 282 (69.5%) patients were diagnosed with dyslipidemia, and 38 patients were diagnosed with mixed dyslipidemia. The 16-/32-week CR rate, pregnant rate, live birth rate, and recurrence did not have significant differences between patients with and without dyslipidemia. Patients with mixed dyslipidemia had a lower 32-week CR rate (42.1% vs.65.5%, P = 0.004) and a longer treatment duration to achieve CR (33.4 weeks vs. 27.0 weeks, P = 0.039, HR: 0.73, 95%CI: 0.53–0.98) than those without mixed dyslipidemia. Multivariate logistic regression analyses demonstrated that mixed dyslipidemia was significantly associated with a lower 32-week CR rate (OR: 0.322, 95% CI: 0.134–0.775, P = 0.011) . Patients with both overweight and mixed dyslipidemia had the lowest 32-week CR rate (12/31, 38.5%, P = 0.007) and longest median treatment duration to CR (34.0 weeks, 95%CI: 25.7–42.3 weeks, P = 0.025) . Mixed dyslipidemia was an independent risk factor for fertility-preserving treatment outcomes in EAH or EEC patients, as this group had a lower 32-week CR rate and a longer treatment duration to achieve CR than those without mixed dyslipidemia.  \nKeywords Endometrial atypical hyperplasia, Endometrial cancer, conservative treatment, Dyslipidemia, Mixed dyslipidemia  \nEndometrial cancer (EC) is one of the most common gynecological malignancies, and the rate of progression of endometrial atypical hyperplasia (EAH) to cancer is nearly 25%1. Progestin and hysteroscopy in fertilitypreserving treatment has recently become particularly important for endometrioid EC (EEC) and EAH patients2. Dyslipidemia refers to abnormal lipid metabolism characterized by any one of hypercholesterolemia, highdensity lipoprotein (HDL)-hypocholesterolemia, low-density lipoprotein (LDL)-hypercholesterolemia, and hypertriglyceridemia. Dyslipidemia is common in EEC or EAH patients seeking fertility-preserving treatment3. Recently, many risk factors have been linked to the complete response (CR) rate of EEC and EAH patients, including overweight and insulin resistance4,5. A previous study showed that dyslipidemia was significantly associated with worse overall survival and recurrence-free survival of EC patients6. Additionally, the use of  \n1Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Shanghai 200011, China. 2Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China.  \n3Shuhan Luo and Manrong Wang have equally contributed to this study and were the first authors. 􀀍 email:  \n[xuezhenluo2013@163.com](xuezhenluo2013@163.com); [leofinger@163.com](leofinger@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nstatins, which are widely prescribed to treat hypercholesterolemia, has been shown to","cbCaihTaUSqvBRmM","https://ap.wps.com/l/cbCaihTaUSqvBRmM","pdf",1899864,"English","# Materials and methods\n## Study population","[{\"question\":\"What was the study’s main purpose?\",\"answer\":\"To assess how dyslipidemia influences outcomes of fertility-preserving treatment in patients with endometrioid endometrial cancer or endometrial atypical hyperplasia.\"},{\"question\":\"How many patients received fertility-sparing treatment, and what groups were compared?\",\"answer\":\"406 patients were included and divided into dyslipidemia (n=282) and non-dyslipidemia (n=124) groups based on lipid status.\"},{\"question\":\"Did dyslipidemia affect complete response, pregnancy outcomes, and recurrence?\",\"answer\":\"Overall, 16- and 32-week complete response rates, pregnancy-related outcomes, and recurrence did not differ significantly between patients with and without dyslipidemia.\"},{\"question\":\"What was the key finding regarding mixed dyslipidemia?\",\"answer\":\"Mixed dyslipidemia was associated with a lower 32-week complete response rate and longer treatment duration to achieve complete response, and it was identified as an independent risk factor, particularly in overweight patients.\"}]","Effects of dyslipidemia on fertility-sparing treatment outcomes in endometrial atypical hyperplasia and endometrial cancer - a large cohort study | PDF",1790151379,23,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/326fe741966b864adb7512b3a8f139e8.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d36b3543273fcdc57479a549bd7263e5.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c19c5dd3453ac4f4601510d50735aceb.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2472b4d1529bee2cc41481bfd036b6c.webp",980,1287]